SupplementsResearch PaperOpen Access

Spermidine Deficiency Drives Food Allergy by Shutting Down Mast Cell Autophagy

Elevated SAT1 enzyme depletes spermidine in allergic tissue, suppressing autophagy in mast cells and amplifying IgE-driven inflammatory cascades.

Monday, September 28, 2026 0 views
Published in Adv Sci (Weinh)
A glass bowl of wheat germ beside mushrooms and aged cheese on a wooden kitchen counter, with a small amber supplement bottle labeled spermidine in the background

Summary

A new study in mice reveals that food allergy triggers upregulation of SAT1, an enzyme that breaks down the longevity-linked polyamine spermidine. This spermidine depletion suppresses autophagy in mast cells — the immune cells central to allergic reactions — causing excessive degranulation and histamine release. The mechanism involves SAT1 physically interacting with a long noncoding RNA called Cdk19os, which in turn silences key autophagy genes Atg5 and Atg7. Crucially, supplementing mice with oral spermidine (10 mg/kg) dramatically reduced allergy symptoms, IgE levels, and intestinal damage. Genetic knockdown of SAT1 produced similar protection. These findings link polyamine metabolism — already known to influence aging and inflammation — to allergic disease, and suggest spermidine supplementation as a potentially accessible dietary intervention.

Detailed Summary

Food allergy affects roughly 8% of children and 5% of adults globally, with prevalence rising 3.5-fold over two decades. Yet disease-modifying therapies remain scarce because the metabolic underpinnings of allergic sensitization and effector responses are poorly understood. This study from China Agricultural University asked whether polyamine metabolism — and specifically the polyamine spermidine, already celebrated in longevity research for its autophagy-inducing properties — plays a causal role in food allergy pathogenesis.

Using a well-validated peanut allergy model in BALB/c mice (n = 8–10 per group), the investigators sensitized animals five times with peanut protein plus aluminum hydroxide adjuvant, then challenged orally. Allergic mice showed dramatically elevated clinical allergy scores, reduced core body temperature (a proxy for anaphylaxis), high allergen-specific IgE, elevated IgG1/IgG2a ratios, and a strongly Th2-skewed cytokine profile (elevated IL-4 and IL-33, reduced IFN-γ). Jejunal spermidine levels measured by HPLC-MS were significantly reduced in allergic animals while putrescine and spermine remained stable, pinpointing a spermidine-specific metabolic shift. SAT1 mRNA was significantly elevated in peripheral blood, jejunum, and lung tissue of allergic mice, a finding corroborated by reanalysis of the public peanut allergy transcriptomic dataset GSE17595. SAT1 upregulation was also confirmed in whey protein- and shrimp-allergic mouse models, indicating a conserved feature across food allergen types.

To test causality, mice received daily oral gavage of spermidine at 10 mg/kg (selected from a dose-response experiment comparing 5, 10, and 20 mg/kg). Spermidine-supplemented mice showed markedly attenuated clinical scores, preserved body temperature, reduced allergen-specific IgE, lower IgG1/IgG2a ratios, decreased IL-4 and IL-33, increased IFN-γ and IL-2, and lower serum histamine and mast cell protease-1 (MMCP-1). Jejunal histology confirmed preserved villus architecture with reduced epithelial shedding and neutrophil infiltration. In a parallel arm, systemic Sat1 knockdown via intravenous siRNA delivery (verified by qPCR) phenocopied spermidine supplementation: reduced allergy scores, decreased IgE, reversed Th2 cytokine polarization, and restored jejunal spermidine levels — all without detectable systemic toxicity.

Mechanistic dissection focused on mast cells, the primary effectors of IgE-mediated allergic reactions. SAT1 was markedly upregulated in mast cells from allergic mice and in IgE/antigen-stimulated bone marrow-derived mast cells (BMMCs) in vitro. SAT1 overexpression promoted degranulation (measured by beta-hexosaminidase release and histamine secretion), while SAT1 knockdown suppressed it. Critically, autophagic flux — assessed by LC3-II accumulation, p62 degradation, and transmission electron microscopy — was significantly impaired in allergic mast cells, and this impairment was rescued by spermidine or SAT1 knockdown. Using RNA immunoprecipitation and co-immunoprecipitation assays, the team identified the lncRNA Cdk19os as a direct SAT1-binding partner. SAT1-Cdk19os interaction suppressed transcription of Atg5 and Atg7, two autophagy-essential genes. Cdk19os knockdown mimicked SAT1 overexpression, worsening allergy; Cdk19os overexpression rescued autophagy and attenuated degranulation. The autophagy inducer rapamycin further confirmed that pharmacological autophagy activation ameliorated allergic responses in vivo.

These findings establish a SAT1→spermidine depletion→Cdk19os→Atg5/Atg7 suppression→impaired autophagy→mast cell hyperdegranulation axis as a novel metabolic-immunological driver of food allergy. For the longevity field, this is significant: spermidine is already known to extend lifespan in model organisms and to support autophagy as an anti-aging mechanism, and this study reveals it also constrains a major allergic inflammatory pathway. The work is conducted entirely in murine models, and translation to humans requires clinical investigation, but it opens a compelling case for dietary spermidine — found naturally in wheat germ, aged cheese, and mushrooms — as a functional food intervention for allergy prevention.

Key Findings

  • Jejunal spermidine levels were significantly reduced in peanut-allergic BALB/c mice vs. controls, while putrescine and spermine remained stable (HPLC-MS, n=4 per group, p<0.05)
  • Oral spermidine supplementation at 10 mg/kg/day reduced clinical allergy scores, allergen-specific IgE, serum IL-4, IL-33, histamine, and MMCP-1, while increasing IFN-γ and IL-2 (n=8, p<0.01–0.0001)
  • SAT1 mRNA was significantly elevated in peripheral blood, jejunum, and lung of allergic mice, and confirmed upregulated in the public GSE17595 peanut allergy transcriptomic dataset
  • SAT1 upregulation was conserved across three allergen models: peanut, whey protein, and shrimp (jejunal tissue, p<0.05 in each)
  • Systemic Sat1 siRNA knockdown reduced allergy scores, decreased IgE and Th2 cytokines (IL-4, IL-5), restored spermidine levels, and reduced histamine and MMCP-1 (n=8–10, p<0.01–0.001)
  • SAT1 physically interacts with lncRNA Cdk19os to suppress Atg5 and Atg7 expression, impairing autophagic flux in mast cells; Cdk19os knockdown worsened allergy while Cdk19os overexpression attenuated degranulation
  • Rapamycin-induced autophagy activation in vivo phenocopied spermidine supplementation, confirming autophagy as the mechanistic bridge between spermidine depletion and mast cell hyperdegranulation

Methodology

BALB/c mice (n=8–10 per group) were sensitized five times with peanut protein plus aluminum hydroxide adjuvant and then orally challenged; additional whey protein and shrimp allergy models validated findings. Interventions included oral spermidine gavage (5, 10, or 20 mg/kg/day for 21 days) and systemic Sat1 siRNA delivered by tail-vein injection. Outcomes spanned clinical scoring, HPLC-MS polyamine quantification, serum IgE/cytokine ELISAs, histology (H&E and toluidine blue), western blot, immunohistochemistry, RNA immunoprecipitation, and autophagic flux assays in bone marrow-derived mast cells. Statistical comparisons used mean ± SEM with significance thresholds of p<0.05 to p<0.0001.

Study Limitations

All experiments were performed in murine models, and the direct translation of the SAT1-Cdk19os-autophagy axis to human mast cell biology and clinical food allergy has not been established. The siRNA knockdown approach used is not currently suitable for clinical application, and the therapeutic window, long-term safety, and optimal dosing of oral spermidine in humans remain unknown. No conflicts of interest were declared by the authors, though the study was funded entirely by the National Key Research and Development Program of China (grant 2023YFF1001600).

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: